Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morgane Rolland

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Plos Pathogens|March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Nature Communications|May 25, 2026
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
Plos Pathogens|December 8, 2020
RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Nature Medicine|March 2, 2011
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trialMorgane Rolland, Sodsai Tovanabutra, Allan C deCamp, et al.
Virus Evolution|September 17, 2021
RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infectionEric Lewitus, Eric Sanders-Buell, Meera Bose, et al.
Science Translational Medicine|April 2, 2025
Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filovirusesThembi Mdluli, Suzanne Wollen-Roberts, Mélanie Merbah, et al.
Research Square|July 3, 2023
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence featuresCraig Magaret, Li Li, Allan deCamp, et al.
Plos Computational Biology|February 4, 2015
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trialPaul T Edlefsen, Morgane Rolland, Tomer Hertz, et al.
The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Plos Pathogens|August 1, 2017
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Plos Pathogens|March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Nature Communications|May 25, 2026
Long-read deep sequencing reveals high rates of multilineage transmission and rapid viral population changes in acute HIV infectionJames I Mullins, Wenjie Deng, Elena E Giorgi, et al.
Plos Pathogens|December 8, 2020
RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Nature Medicine|March 2, 2011
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trialMorgane Rolland, Sodsai Tovanabutra, Allan C deCamp, et al.
Virus Evolution|September 17, 2021
RV144 vaccine imprinting constrained HIV-1 evolution following breakthrough infectionEric Lewitus, Eric Sanders-Buell, Meera Bose, et al.
Science Translational Medicine|April 2, 2025
Ebola virus vaccination elicits Ebola virus-specific immune responses without substantial cross-reactivity to other filovirusesThembi Mdluli, Suzanne Wollen-Roberts, Mélanie Merbah, et al.
Research Square|July 3, 2023
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence featuresCraig Magaret, Li Li, Allan deCamp, et al.
Plos Computational Biology|February 4, 2015
Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trialPaul T Edlefsen, Morgane Rolland, Tomer Hertz, et al.
The Lancet. HIV|April 20, 2019
Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trialTrevor A Crowell, Donn J Colby, Suteeraporn Pinyakorn, et al.
Plos Pathogens|August 1, 2017
Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infectionGustavo H Kijak, Eric Sanders-Buell, Agnes-Laurence Chenine, et al.
Pageof 12